The Glioblastoma Drug Discovery Group announces that osimertinib significantly prolongs the survival of immunocompromised mice bearing intracranial EGFRvIII-positive glioblastoma! These data …
Monthly Archives: November 2016
Press Release: Dr. Steven Keating, Our New Advisor
The Glioblastoma Drug Discovery Group is proud to have brain tumor survivor, Dr. Steven Keating, Ph.D., as a volunteer advisor. …